Results: Max Healthcare Institute Limited Beat Earnings Expectations And Analysts Now Have New Forecasts

As you might know, Max Healthcare Institute Limited (NSE:MAXHEALTH) recently reported its quarterly numbers. Revenues missed the mark, coming in 17% below forecasts, at ₹21b. Statutory profits were better overall though, with per-share profits of ₹5.02 being a notable 17% above what the analysts were modelling. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the consensus forecast from Max Healthcare Institute's 25 analysts is for revenues of ₹105.1b in 2026. This reflects a major 32% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to shoot up 33% to ₹18.60. In the lead-up to this report, the analysts had been modelling revenues of ₹105.4b and earnings per share (EPS) of ₹18.51 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

Check out our latest analysis for Max Healthcare Institute

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹1,269. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Max Healthcare Institute, with the most bullish analyst valuing it at ₹1,548 and the most bearish at ₹614 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Max Healthcare Institute's rate of growth is expected to accelerate meaningfully, with the forecast 75% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 21% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 20% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Max Healthcare Institute is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Max Healthcare Institute going out to 2028, and you can see them free on our platform here..

You can also see whether Max Healthcare Institute is carrying too much debt, and whether its balance sheet is healthy, for free on our platform here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.